News & Comment

Filter By:

Year
  • Treatment with the small interfering RNA patisiran preserves functional capacity and improves health status and quality of life in patients with transthyretin cardiac amyloidosis, according to data from the 12-month double-blind period of the ongoing APOLLO-B trial.

    • Irene Fernández-Ruiz
    Research Highlight
  • Transcatheter aortic valve implantation (TAVI) has become an important treatment option for aortic stenosis, even among younger patients, with similar rates of efficacy as compared with surgical valve replacement. However, complications including device failure persist; these can be addressed by surgical explantation and repeat TAVI. Ongoing research emphasizes the long-term potential of TAVI as an alternative to surgical intervention for aortic stenosis.

    • Marco Barbanti
    • John G. Webb
    Clinical Outlook
  • For patients with heart failure and reduced left ventricular ejection fraction, intravenous iron is likely to deliver clinical and prognostic benefits for those with anaemia and transferrin saturation <20%, especially if serum ferritin exceeds 100 μg/l. A serum ferritin of <100 μg/l does not appear to be useful as a marker of iron deficiency.

    • John G. F. Cleland
    Comment
  • NAD-dependent protein deacetylase sirtuin 2 is a key protective mediator against cardiac ageing, according to a study in non-human primates.

    • Irene Fernández-Ruiz
    Research Highlight
  • SARS-CoV-2 infects macrophages, especially lipid-laden foam cells, in coronary atherosclerotic plaques in patients with COVID-19; this infection initiates a strong proatherogenic inflammatory response, which might contribute to the ischaemic cardiovascular complications in these patients.

    • Gregory B. Lim
    Research Highlight
  • In a study published in Nature, Jia and colleagues use advanced optical electrophysiology tools coupled with 3D-printed moulds to capture the very first heartbeat of zebrafish.

    • Karina Huynh
    Research Highlight
  • The metabolic maturation of mammalian cardiomyocytes that occurs during the early postnatal period shapes the epigenetic landscape of cardiomyocytes and creates a barrier for cell division, but reversing this remodelling process can restore the reparative capacity of the heart in mice, according to a study published in Nature.

    • Irene Fernández-Ruiz
    Research Highlight
  • Despite the high consumption of fermented foods and beverages worldwide, their role in a healthy diet is still up for debate. Some fermented beverages have been demonstrated to protect against cardiovascular disease, but many aspects of the effects of fermented foods on cardiovascular health are uncertain. Better-designed studies are warranted.

    • Ramon Estruch
    • Rosa M. Lamuela-Raventós
    Comment
  • The population of patients who undergo cardiac surgery is becoming older and more medically complex, and frailty is increasingly prevalent. Prehabilitation is a multicomponent programme intended to better prepare these vulnerable patients for the stresses of surgery. Nonetheless, the effectiveness, implementation and effects on long-term outcomes of prehabilitation have not been clearly established. In particular, frailty might not be easily mitigated by prehabilitation.

    • Atilio Barbeito
    • Daniel E. Forman
    Clinical Outlook
  • Two studies now report that TET2-driven clonal haematopoiesis of indeterminate potential (CHIP) is associated with poor prognosis in patients with heart failure (HF) and preserved ejection fraction and that DNMT3A CHIP driver mutations promote dysregulated gene expression profiles that are associated with inflammation in monocytes in the setting of HF.

    • Karina Huynh
    Research Highlight
  • The link between migraine and cardiovascular disease is complex and involves overlapping mechanisms, such as endovascular disturbances. Challenges in measuring migraine, in distinguishing between causation and prediction, and in the understanding of clinical implications highlight the need for further research to guide treatment and cardiovascular risk assessment for the millions of individuals living with migraine.

    • Tobias Kurth
    • Pamela M. Rist
    Clinical Outlook
  • In patients with heart failure (HF) with preserved ejection fraction and obesity, treatment with the glucagon-like peptide 1 receptor agonist semaglutide (2.4 mg) leads to large reductions in HF-related symptoms and physical limitations, improves exercise function and decreases body weight compared with placebo, according to the STEP-HFpEF trial.

    • Irene Fernández-Ruiz
    Research Highlight
  • The FIRE trial showed that complete revascularization improves outcomes in older patients with myocardial infarction (MI) and multivessel disease compared with culprit-lesion-only revascularization, whereas the MULTISTARS AMI trial reported that immediate multivessel revascularization is non-inferior to staged revascularization in patients with ST-segment elevation MI.

    • Karina Huynh
    Research Highlight
  • New data from the ECLS-SHOCK trial and a meta-analysis indicate that the routine use of venoarterial extracorporeal membrane oxygenation does not increase survival in patients with myocardial infarction-related cardiogenic shock.

    • Gregory B. Lim
    Research Highlight
  • Two clinical trials presented at the ESC Congress 2023 provide conflicting evidence on the use of optical coherence tomography to guide percutaneous coronary intervention.

    • Irene Fernández-Ruiz
    Research Highlight